Drapkin Kimberlee C 4
4 · Climb Bio, Inc. · Filed Jun 8, 2026
Research Summary
AI-generated summary of this filing
Climb Bio Director Kimberlee C. Drapkin Receives 40,000-Share Award
What Happened
Kimberlee C. Drapkin, a director of Climb Bio, received a grant of 40,000 derivative shares (reported acquisition price $0) on June 5, 2026. The filing reports this as an award/acquisition (code A). No cash changed hands in the filing; the award carries a vesting condition described in the footnote.
Key Details
- Transaction date: June 5, 2026; Form 4 filed June 8, 2026 (within the usual two-business-day reporting window).
- Amount: 40,000 derivative shares; reported price/acquisition amount: $0; total reported value: $0.
- Shares owned after transaction: Not specified in this filing.
- Footnote: The shares will vest on the earlier of June 5, 2027 or immediately prior to the next annual meeting of stockholders, subject to Drapkin’s continued service through that date.
- Exhibit: 24.1 (Power of Attorney) included with the filing.
Context
This was an equity award to a director (not a purchase or a sale). Derivative grants like this typically vest over time and do not indicate an immediate sale or cashless exercise. For retail investors, awards are routine for director compensation; they signal alignment with shareholder interests but are not a direct market bet.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-05+40,000→ 40,000 totalExercise: $10.55Exp: 2036-06-04→ Common Stock (40,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.